SCHEMBL17684133

SCHEMBL17684133

OC1CCC2(CC1)OC2c1cccc(Br)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 7/20 0.39
RCOR1 Q9UKL0 4/20 0.35
DRD2 P14416 1/20 0.35
DRD1 P21728 1/20 0.35
DRD4 P21917 1/20 0.35
DRD5 P21918 1/20 0.35
DRD3 P35462 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
MAPT P10636 1/20 0.33
HDAC4 P56524 1/20 0.33
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
RAB9A P51151 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
HCRTR1 O43613 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17684450 0.85 KDM1A (0.39) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL17684216 0.83 KDM1A (0.42) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL17684167 0.82 HSD11B1 (0.39) KDM1ARCOR1HTR2AHTR2CHTR2B
SCHEMBL17684127 0.80 KDM1A (0.40) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL17684518 0.75 HTR2A (0.34) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL17684310 0.75 KDM1A (0.38) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL11837847 0.72 KDM1A (0.47) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL1813507 0.70 KDM1A (0.44) KDM1ARCOR1DRD2DRD1DRD4
SCHEMBL17735939 0.68 KDM1A (0.39) KDM1ARCOR1HTR2AHTR2CHTR2B
SCHEMBL17684315 0.68 TAAR1 (0.37) KDM1ARCOR1HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160130278-A1 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-05-12 US disclosed
US-20160130278-A1 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-05-12 US disclosed
US-20160130278-A1 GLYCINE TRANSPORTER INHIBITOR TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-05-12 US disclosed
EP-3009421-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2016-04-20 EP disclosed
EP-3009421-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2016-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130278-A1 GLYCINE TRANSPORTER INHIBITOR SLC1A2, SLC6A5, SLC18A2 KDM1A 4612/4885RCOR1 3807/4885DRD2 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.